ProQR Therapeutics N.V. Культура компании

Mr. Daniel A. de Boer has been the Chief Executive Officer at ProQR Therapeutics N.V. since February 21, 2012 and serves its Member of Management Board. Mr. de Boer is responsible for the overall strategy and general business at ProQR Therapeutics. He is a passionate and driven entrepreneur and advocate for CF patients and has assembled an experienced team of successful biotech executives as co-founders and early investors. He is a serial entrepreneur in IT, he founded and led a number of tech companies through phases of growth, initiating development and launch of several IT related products in several European countries. He served as a founder and Chief Executive Officer of RNA Systems from 2009 to 2011. From 2007 to 2008, he was Founder and Chief Executive Officer of PC Basic and from 2005 to 2011, he served as a Founder and Chief Executive Officer of Running IT.

Ms. Smital Shah has been Chief Financial Officer of ProQR Therapeutics N.V. since October 3, 2014. Ms. Shah has a 12-year track record of management and leadership experience in the biopharmaceutical industry as well as in investment banking, with a particular focus on financial strategy and capital markets. She joined the ProQR Therapeutics from Gilead Sciences, Inc., where she managed its debt, cash and investment portfolios from August 2012 to September 2014. From 2007 to 2012, Ms. Shah worked in investment banking at Leerink Partners LLC and JPMorgan Chase, where she focused on capital raising and strategic transactions in the biotechnology companies sector. Prior to this, she held various research and development roles at Johnson & Johnson from 2002 to 2007. Ms. Shah holds Bachelor's and Master's degrees in Chemical Engineering as well as a Masters of Business Administration from the University of California at Berkeley.

Mr. Rene K. Beukema has been Chief Corporate Development Officer, General Counsel and Corporate Secretary at ProQR Therapeutics N.V. since April 2014 and serves its Member of Management Board. Mr. Beukema joined ProQR in September 2013 and is a seasoned in-house corporate lawyer in the Dutch biotechnology arena. He is co-founder and advisor of Mytomorrows N.V., a Dutch life sciences company. He was a Venture Partner at Aescap Venture. He joined Aescap Venture on January 1, 2012 and added significant value to the Aescap Venture's team and its portfolio of private life sciences investee companies. He has strategic thinking combined with broad knowledge in setting up businesses as well as experience with mergers, acquisitions, divestitures and licensing within the field of Life Sciences. From October 2000 to 2011, he served as a General Counsel and Corporate Secretary at Crucell N.V. He was instrumental in building Crucell from a loss making, privately financed company to one of the most successful publicly listed independent vaccine companies in the world. He served as the Corporate Secretary & General Counsel at IntroGene since 1999. Prior to joining Crucell, he served as the Senior Legal Counsel at GE Capital/T.I.P. Europe Plc from 1994 to 1999. Mr. Beukema served as the Legal Counsel for TNT Express Worldwide N.V from 1991 to 1994. He is a member of the VU Medical Cancer Center children in Amsterdam. He holds a post-doctoral degree in corporate law from the University of Nijmegen in co-operation with the Dutch Association of In-house Counsel (Nederlands Genootschap van Bedrijfsjuristen) and a Master's degree in Dutch law from the University of Amsterdam.

Dr. Robert Friesen, Ph.D., has been Senior Vice President of Science & Early Development at ProQR Therapeutics N.V. since October 26, 2017. Dr. Friesen is responsible to oversee the scientific advancement of ProQR Therapeutics and responsible for non-clinical development. He served as Head of Innovation at ProQR Therapeutics N.V. since June 2016. He served as a Director of Pre-clinical development of Morphosys AG since July 2005. He has many years of experience in pharmaceutical development. He joined MorphoSys from Dutch biopharmaceutical company AM-Pharma BV, where he served as a Vice President of Research and Pre-Clinical Development he was responsible for the development of lMorphosys Ag lead compounds from the research stage into clinical development. He served as Vice President and Head of Biologics Research within Janssen R&D, a Johnson & Johnson company, where he led a global team of over 200 scientists responsible for the discovery and early development of biotherapeutics for all therapeutic areas. Dr. Friesen held a management position at the department of Innovative Drug Delivery Systems at Biomade Technology Foundation - a Dutch research institute developing medical applications in the area of nanotechnology. He has authored a number of publications in high impact scientific journals and participated in numerous invited lectures. He has also been awarded multiple patents in the field of biotechnology. Dr. Friesen earned his Ph.D. in Biochemistry from the University of Texas. He obtained a M.S. in Biology from the University of Utrecht.

Dr. Peter Adamson, Ph.D., also known as Pete, has been Senior Vice President of Ophthalmology Franchise at ProQR Therapeutics N.V. since October 26, 2017 and served as its Head of Ophthalmology Research since April 2015 until October 26, 2017. Dr. Adamson serves as the Chief Executive Officer and Consultant of Ophthaltec Limited. Dr. Adamson joined Ophthaltec from GlaxoSmithKline where he served as Vice President and Head of Inflammation Biology (and ophthalmology) at GSK's Centre of Excellence in External Drug Discovery (CEEDD) and Head of Cellular Pharmacology, Cardiovascular & Urological Diseases. Prior to GSK, he served as a Senior Investigator at University College London's Institute of Ophthalmology from 1994 to 2004. He worked as a postdoctoral researcher at the Institute of Cancer Research and Vascular Biology Research Centre before taking up an academic position at the UCL Institute of Ophthalmology from 1994-2004 where he was a group leader and Reader in Molecular Pathology. Dr. Adamson has over 21 years of experience gained in both pharmaceutical and academic sectors, with a specific focus on the fields of inflammatory and ophthalmic diseases. Dr. Adamson has authored over 100 peer-reviewed scientific publications in the domains of inflammation, ophthalmology and neurology and retains an honorary appointment at UCL, Institute of Ophthalmology where he is Professor of Molecular Pathology (Ophthalmology). Dr. Adamson holds his Ph.D. in Biochemistry from the University of London's Institute of Psychiatry and a B.Sc. in Biochemistry from the University of Newcastle-upon-Tyne.

Dr. David M. Rodman, M.D. has been Chief Development Strategy Officer of ProQR Therapeutics N.V. since March 27, 2017. Dr. Rodman served as the Chief Medical Officer and Executive Vice President of Discovery at Nivalis Therapeutics, Inc. since April 18, 2016 until January 15, 2017. Dr. Rodman lead the discovery and clinical development strategy and operations for Nivalis, including advancement of N91115. Dr. Rodman served as an Executive Vice President of Research & Development at miRagen Therapeutics, Inc. from March 25, 2014 to April 18, 2016 and served as its Chief Medical Officer. Dr. Rodman is an accomplished industry veteran and has significant translational medicine and clinical development experience. Dr. Rodman has more than 25 years of experience in bench to bedside research. Prior to joining miRagen, Dr. Rodman served as a Vice President of Clinical Development and Head of Respiratory Clinical Development at Vertex Pharmaceuticals Incorporated, where he led teams in the development of Vertex's cystic fibrosis programs, including Orkambi. Before that, he served as Executive Director, Respiratory Translational Medicine at the Novartis Institutes for Biomedical Research. Dr. Rodman has led cross-functional teams across the R&D spectrum from basic cell and molecular biology, through first-in-human proof-of-concept trials, to successful pivotal trials. The teams he has led have delivered multiple successful IND and CTA applications in the US, Europe and developing countries. While at Vertex, teams he led participated in the development of its portfolio of approved and investigational cystic fibrosis medicines. Prior to Vertex, Dr. Rodman held roles of increasing responsibility at the Novartis Institutes for Biomedical Research. He has also served in several academic leadership positions, including Director of the Center for Genetic Lung Disease at the University of Colorado School of Medicine, Director of the Cystic Fibrosis Center at National Jewish Medical and Research Center and Director of the Adult Cystic Fibrosis Program at the University of Colorado Health Sciences Center. He is an Established Investigator and a Fellow of the American Heart Association. He is an elected Member of the American Society for Clinical Investigation. He was a Founding Member of the Cystic Fibrosis Therapeutics Development Network. Dr. Rodman was a tenured Professor of Medicine at the University of Colorado. He has authored more than 100 publications. He holds a Medical Degree from the University of Pennsylvania.

Mr. Gerard Platenburg has been the Chief Innovation Officer of ProQR Therapeutics N.V. since February 2014 and has been its Chairman of Advisory Board since August 2017. Mr. Platenburg is a co-founder of ProQR Therapeutics. He has an extensive background in RNA modulation and orphan drug discovery and development and is in charge of ProQR's innovation unit. He has more than 20 years senior managerial experience, which he gained during his different operational and leadership roles in growing biotech companies. He was Founder of BioMarin Nederland B.V. (formerly, Prosensa Holding N.V. and Prosensa B.V.) and serves as its Chief Development Officer. He held various positions at BioMarin Nederland from April 2002 to May 2009. He worked at Isa Pharmaceuticals B.V. from June 2009 to January 2014. He served as Chief Executive Officer of ISA Pharmaceuticals B.V. He joined BioMarin Nederland in 2002 as one of the founders and responsible for general management, including investor relations. He served as the Chief Executive Officer of BioMarin Nederland. He joined Pharming in 1989 as one of the founding scientific crew. He worked at Pharming B.V. until March 2002. He serves as a Member of Scientific & Clinical advisory board at BioMarin Nederland B.V. He served as the sole member of supervisory board at ProQR Therapeutics from August 2012 to December 2013. Mr. Platenburg is the recipient of the Ernst and Young award for the best business plan in 2000. He received a master's degree in chemistry and molecular biology from Leiden University in 1987 and pursued PhD work at Leiden University.